Welcome to our dedicated page for Electromed SEC filings (Ticker: ELMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Electromed, Inc. filings document formal disclosures for a Minnesota operating company focused on airway clearance technologies. Recent Form 8-K reports furnish quarterly financial results, Regulation FD investor presentations, share repurchase authorization disclosures, and material financing information tied to a senior secured revolving credit facility.
The company's proxy and shareholder-vote filings cover director elections, auditor ratification, advisory executive compensation votes, board and governance matters, and equity-compensation disclosures. These records also describe capital-allocation actions, debt covenants, financial condition updates, and exhibit materials associated with press releases, credit agreements, and investor presentations.
Electromed, Inc. (ELMD) Form 4 filed for James L. Cunniff, CEO and President. The filing reports a disposition of 1,291 common shares on 09/02/2025 at $23.95 per share to satisfy tax withholding related to vested restricted stock, reducing his holdings to 130,751 shares. On the same date he was granted 17,000 restricted shares scheduled to vest in three equal annual installments beginning September 2026, and received an employee stock option for 31,100 shares at a $23.95 exercise price exercisable in three equal annual installments beginning September 2026 and expiring 09/02/2035, leaving 31,100 options outstanding.
Electromed, Inc. (ELMD) reporting person Bradley M. Nagel, CFO, made scheduled equity transactions on 09/02/2025 that increased his overall beneficial stake. He disposed of 562 common shares to satisfy tax withholding from restricted stock vesting at an average price of $23.95, leaving him with 16,538 shares prior to additional acquisitions. He acquired 5,300 restricted shares (no cash price) that vest in three equal annual installments beginning September 2026, and received an employee stock option to buy 9,800 shares at a $23.95 exercise price expiring 09/02/2035, vesting in three equal annual installments from September 2026. After the transactions, his beneficial ownership rose to 21,838 common shares plus 9,800 option shares exercisable in the future.
Electromed, Inc. reported details in its Form 10-K that describe its business, capital structure and selected balance sheet and operating items. The company had 8,349,176 shares issued and outstanding as of June 30, 2025, down from 8,637,883 a year earlier after share repurchase programs that retired 280,017 and 220,899 shares in prior authorizations for total costs of $5,000,000 each and are now exhausted. The company maintains a $2.5 million secured line of credit with interest at prime less 1.0% (prime was 7.50% at June 30, 2025). Operating lease liabilities increased to $198,000 from $87,000 and related right-of-use assets and lease terms are disclosed. As of June 30, 2025, unrecognized compensation expense related to non-vested awards was $1,351,000 expected to be recognized over weighted-average periods near two years. The effective tax rates were 26.7% and 26.8% for fiscal 2025 and 2024. The Audit Committee and Board provide oversight of a cybersecurity risk management program co-led by senior management and third-party providers.
Electromed, Inc. disclosed that it has issued a press release reporting its financial results for the fourth quarter and fiscal year ended June 30, 2025, and furnished that press release as Exhibit 99.1 to this Form 8-K. The company also updated its investor presentation and furnished it as Exhibit 99.2, noting that the presentation may be used in meetings with investors and analysts.
The filing provides notice that the company has made results and updated presentation materials available to the market, but it does not include the financial metrics or narrative from the press release within the filing itself; interested parties must refer to the referenced exhibits for the detailed results and figures.